Novartis raised its full-year profit guidance on Tuesday after third-quarter core operating income rose 10% at constant currencies to $6.04bn, well ahead of the $5.51bn analysts expected, as Kisqali and newer drugs outran generic competition. A $1.9bn writedown on del-desiran, the muscle-disease drug that failed in September, cut reported operating income by 59%.
A profit beat on in-line sales
Net sales were $14.52bn, up 4% both at constant currencies and in dollars, matching the $14.5bn forecast in the consensus collected by Newsquawk. The surprise came lower down: the core operating margin widened by 2.3 percentage points to 41.6%, and core earnings per share of $2.46 beat the $2.28 expected.
Volume growth added 14 percentage points to sales, while generic competition took away 9 points and lower prices one more. Free cash flow fell 18% to $5.1bn.
The new 2026 guidance
- Core operating income: in line with last year or up by a low single-digit percentage, from a low single-digit decline before
- Net sales: growth by a low single-digit percentage, unchanged
- Currency: a positive effect of about one percentage point on both if late-October exchange rates hold
Chief executive Vas Narasimhan said priority brands and launches more than offset generic erosion, showing "the replacement power of the business".

Novartis: share price, chart and news
The brands doing the work
Breast cancer drug Kisqali added the most growth, followed by multiple sclerosis treatment Kesimpta. The fastest growers were Scemblix, for a type of leukaemia, and cholesterol drug Leqvio, helped by its inclusion in China's national reimbursement list. Heart failure drug Entresto went the other way.
| Medicine | Q3 sales | Growth (cc) |
|---|---|---|
| Cosentyx | $1,857m | +9% |
| Kisqali | $1,821m | +37% |
| Kesimpta | $1,484m | +22% |
| Pluvicto | $674m | +20% |
| Scemblix | $593m | +67% |
| Leqvio | $506m | +63% |
| Entresto | $1,165m | -38% |
Markets: indices, currencies and commodities
The del-desiran writedown
The reported figures carry the cost of September's setback. Del-desiran, a treatment for myotonic dystrophy type 1 that Novartis gained through its $12bn purchase of Avidity Biosciences, missed the main goal of the Phase III HARBOR trial. Novartis has now booked a $1.9bn partial impairment on the asset.
That charge, booked in research and development costs, took operating income down 59% to $1.84bn. With higher interest costs on top, net income fell 70% to $1.20bn. Earnings per share fell to $0.63 from $2.04. Core figures, which Novartis uses for its guidance, exclude the charge.
The company said it saw signs of clinical activity in secondary measures and is working through the development path with regulators. It also pointed to progress in the other Avidity programmes: del-zota, for a form of Duchenne muscular dystrophy, won FDA Priority Review in the quarter.
A share price that has already recovered
The HARBOR failure on 8 September followed within days a separate Phase III miss for pelacarsen, a heart drug, and the shares fell 10.89% that day. They lost 13.54% that week to close at CHF 112.04.
They have since risen in five of six weeks and closed on Friday at CHF 128.00, up 14.2% from that low and close to the CHF 129.58 they closed at on 4 September, the day Novartis announced the pelacarsen result. Some of the good news in today's figures may therefore already be expected.
What investors watch now
Swiss trading opens after this release, and the first test is whether the profit beat and guidance upgrade outweigh the size of the writedown. Beyond the session, investors will watch how fast generic competition eats into older brands next year, and whether Kisqali and Kesimpta can keep growing at this pace.
Capital returns are the other thread. Novartis still has up to $4.9bn left to buy under the $10bn buyback it announced in July 2025, while net debt rose to $37.4bn at the end of September from $21.9bn at the end of 2025, mainly because of acquisitions. Full HARBOR data are due at a medical congress, which will shape what del-desiran is still worth.
Sources
- Novartis: Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance
- Newsquawk: Novartis (NOVN SW) Q3 2026 (USD): Net Sales 14.5bln (exp. 14.5bln), Adj. Operating Income 6.04bln (exp. 5.51bln)
- Novartis: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen
- pharmaphorum: Novartis falls sharply on another major R&D setback
- BMK News market data (delayed exchange data)








